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Abstract
Background: The emergence and spread of antimicrobial resistance (AMR) present a challenge to disease control
in East Africa. Resistance to beta-lactams, which are by far the most used antibiotics worldwide and include the
penicillins, cephalosporins, monobactams and carbapenems, is reducing options for effective control of both Gram-
positive and Gram-negative bacteria. The World Health Organization, Food and Agricultural Organization and the
World Organization for Animal Health have all advocated surveillance of AMR using an integrated One Health
approach. Regional consortia also have strengthened collaboration to address the AMR problem through
surveillance, training and research in a holistic and multisectoral approach. This review paper contains collective
information on risk factors for transmission, clinical relevance and diversity of resistance genes relating to extended-
spectrum beta-lactamase-producing (ESBL) and carbapenemase-producing Enterobacteriaceae, and Methicillin-
resistant Staphylococcus aureus (MRSA) across the human, animal and environmental compartments in East Africa.
Main body: The review of the AMR literature (years 2001 to 2019) was performed using search engines such as
PubMed, Scopus, Science Direct, Google and Web of Science. The search terms included ‘antimicrobial resistance
and human-animal-environment’, ‘antimicrobial resistance, risk factors, genetic diversity, and human-animal-
environment’ combined with respective countries of East Africa. In general, the risk factors identified were
associated with the transmission of AMR. The marked genetic diversity due to multiple sequence types among
drug-resistant bacteria and their replicon plasmid types sourced from the animal, human and environment were
reported. The main ESBL, MRSA and carbapenem related genes/plasmids were the blaCTX-Ms (45.7%), SCCmec type
III (27.3%) and IMP types (23.8%), respectively.
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Conclusion: The high diversity of the AMR genes suggests there may be multiple sources of resistance bacteria, or
the possible exchange of strains or a flow of genes amongst different strains due to transfer by mobile genetic
elements. Therefore, there should be harmonized One Health guidelines for the use of antibiotics, as well as
regulations governing their importation and sale. Moreover, the trend of ESBLs, MRSA and carbapenem resistant
(CAR) carriage rates is dynamic and are on rise over time period, posing a public health concern in East Africa.
Collaborative surveillance of AMR in partnership with regional and external institutions using an integrated One
Health approach is required for expert knowledge and technology transfer to facilitate information sharing for
informed decision-making.
Keywords: Genetic diversity, Risk factors, Antimicrobial resistance, Human-animal-environment, East Africa
Background
The emergence and the spread of antimicrobial resistance
(AMR) presents a global challenge to diseases control.
AMR can occur naturally following exposure to anti-
microbial agents in the management of veterinary and
human clinical cases [1]. The acquisition and spread of
AMR can be attributed to ecological connectivity and
presence in the community, of a previously acquired re-
sistance gene, which can be denoted as a founder effect
[2]. In resource-limited settings, the availability of antibi-
otics over the counter and without prescription mainly for
self-treatment of suspected infections contributes to
AMR. Of particular concern is the emergence of multi-
drug resistant (MDR) bacteria such as methicillin-resistant
Staphylococcus aureus (MRSA) and extended spectrum
beta-lactamase (ESBL)-producers. For instance, MDR in-
vasive non-typhoidal Salmonella (iNTS) disease poses a
major challenge to the clinical management of infections
in resource-limited settings especially as alternative more
effective antibiotics remain either unaffordable or simply
unavailable for majority of patients [3].
In East Africa, resistance to commonly used antibiotics
have been reported in humans [4–11], livestock [12, 13],
wildlife [14] and environment [15, 16]. There is a worry-
ing trend of increasing prevalence of AMR [17]. In
recent years, the numbers of infections due to the ESBL-
producing Enterobacteriaceae (ESBL-PE), MRSA, and
carbapenem resistance (CAR) have increased, and they
are now been recognized as “infections of concern” to
East African and wider international populations. The
carbapenem-based antibiotics, which are considered as
“antibiotics of last resort” or “last-line agents”, have been
compromised by the emergence of MDR Gram-negative
bacteria [18]. In Sub-Saharan African countries, infec-
tion, and control measures against MRSA amplify the
challenges in dealing with the AMR epidemic [19].
MRSA is primarily mediated by the mecA gene, located
in staphylococcal cassette chromosome mec (SCCmec)
that codes for a 78 kDa penicillin-binding protein (PBP2a),
that has decreased affinity to methicillin and all beta-
lactam antibiotics [20, 21]. Likewise, ESBL-PE possess a
threat [22], associated with pediatric septicemia and urin-
ary tract infections [23]. The largest ESBL group are the
mutants blaTEM and blaSHV β-lactamases followed by
blaCTX-M enzymes [24]; others include blaOXA-type β-
lactamases, PER, VEB, GES.BES.TLA, SFO, IBC groups
[24]. The co-emergence of ESBLs and carbapenemase-
encoding plasmids facilitate selection for other resistance
determinants for other antimicrobial classes, including
aminoglycosides and fluoroquinolones, a key feature that
fosters the spread of MDR in Enterobacteriaceae [25]. Fur-
ther, a plasmid with ESBL determinants can also carry
aminoglycosides and ciprofloaxcin resistance (CR) deter-
minants. Such co-existence of resistance mutations on
plasmids or ESBL related genes is not uncommon [26].
In East Africa, CR has been reported in Enterobacteri-
aceae and other gram-negative bacteria [9, 17, 27–32].
The high prevalence of CAR Enterobacteriaceae among
Klebsiella pneumoniae and Escherichia coli present a
challenge against treatment of the carbapenemase-
producing Enterobacteriaceae infections [33]. Despite
the fact that colistin is effective in the treatment of
Gram-negative infections, it is toxic with a poor treat-
ment outcome [34]. Resistance due to carbapenem antibi-
otics is mediated through the production of carbapenemases
beta-lactamases enzymes such as veron integron metallo-
beta-lactamases, imipenemase, K. pneumoniae carbape-
nemases, oxacillinase-48, and New Delhi Metallo-beta-
lactamase_1, which are encoded by “blaVIM”, “blaIMP”,
“blaKPC”, “blaOXA-48”, and “blaNDM” genes respec-
tively [9].
In resource-limited settings, knowledge of the burden,
distribution, and diversity of resistance genes in humans,
animals and the environment is scarce [35]. Despite in-
creasing research on AMR in such settings, few studies
have adopted an integrated “One Health” (OH) approach
to understand the transmission dynamics of AMR across
humans, animals and the environment. Most AMR stud-
ies in resource-limited settings are human-focused [36],
and constitute the majority of current knowledge [35].
Nevertheless, major policy reforms have been imple-
mented in developing countries to generate a collective
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response to address AMR and antimicrobial use, set
within a holistic and multisectoral One Health frame-
work. In Tanzania, the SACIDS Foundation for One
Health has focused on the burden of AMR in the south-
ern African region, and has been providing support in
the local and global fight against AMR. The SACIDS
Foundation for One Health in partnership with the
American Society for Microbiology implemented the
Tanzania National Action Plan on AMR through the
Fleming Fund Initiative to support AMR surveillance
strategy. This strategy attempts to address the major
gaps in AMR data collection and analysis, whilst
strengthening antimicrobial stewardship. Furthermore,
the Africa Centers for Disease Control and Prevention
Framework for AMR in collaboration with public health
institutions and leaders from human and animal health
sectors have established a network for the surveillance of
AMR. This network aims to measure, prevent, and miti-
gate the effects arising from drug resistance organisms.
Our paper presents and analyzes information on AMR
from published articles in East Africa in order to provide
an overview of risk factors for AMR transmission and
genetic diversity of ESBL, MRSA and CAR resistance
genes, as well as a consideration of the role of humans,
animals and the environment in emergence and spread
of AMR. Further, the review paper addresses the clinical
relevance of ESBL, MRSA and CAR bacteria and initia-
tives which have been taken by regional consortia. These
initiatives, in collaboration with external institutions, are
addressing the AMR problem through an integrated
One Health approach, and providing evidence-based in-
formation for decision making in the management of
AMR clinical cases.
Materials and methods
The review of the literature was performed using search
engines such as PubMed, Scopus, Science Direct, Google,
Web of Science. Literature search was extended to involve
repositories and sector ministries websites; however, no
additional information was found. Search terms included
‘antimicrobial resistance and human-animal-environment,
risk factors and predictors’, ‘antimicrobial resistance in
human and animal populations’, prevalence and genotypic
characterization of antimicrobial resistance’, methicillin-
resistant Staphylococcus aureus’, ‘beta-lactamase genes
and phenotypes’ Carbapenems resistance genes; ‘anti-
microbial resistance genetic diversity and human-animal-
environment’ combined with respective countries in East
Africa including Burundi, Kenya, Rwanda, Tanzania and
Uganda. The inclusion criteria included articles published
between January 2001 and December 2018, which charac-
terized AMR genes using genotypic methods in animals,
humans and the environment. The exclusion criteria in-
volved studies that did not utilize genotypic methods to
identify resistance genes and sequence types of the AMR
genes in the bacterial isolates.
Non-English language articles from French Speaking
African countries such as Rwanda and Burundi were also
excluded. The data were extracted using a template set
of characteristics, including bacteria species, their origin
(e.g. human, animal and environmental compartments),
the proportion of the resistance genes, genotypic
methods used for identification of AMR genes, se-
quence/clones/lineage types, plasmid replicon type and
country of isolation. Further, descriptive statistics was
performed to indicate trends of ESBLs, CARs and MRSA
genes for the screened articles. The proportions of AMR
genes from various pathogens in humans, animals and
environment were correlated all-over the time-period for
the screened studies using STATA version 14 (StataCorp
LP, College Station, TX, USA), taking into consideration
the time-period of recovered isolates. A p-value of < 0.05
considered statistically significant.
Results
The risk factors for emergence and transmission of AMR
in animals, humans and the environment
The risk factors associated with the transmission of
AMR genes varied within and between countries
(Table 1), and can be broadly divided into five major
types: (a) human practices, (b) demographic factors, (c)
history of diseases and co-morbidities, (d) antibiotic use,
and (e) hospitalization. We consider each in turn.
Human practices
Transmission of AMR has been associated with practices
involved in food production and animal husbandry [1].
Such practices include the use of antimicrobials in feeds
as growth-promoters and to prevent infections [51–53] .
For instance, Basulira et al. [49] reported a higher me-
dian concentration of antimicrobials such as beta-lactam
antibiotics in adult carcass beef compared to young
carcass beef samples. Such high levels of beta-lactam in
feeds might be attributed by the indirect use of β-lactam
antibiotics and tetracycline in feeds, drenches, drinking
water and feed additives in the fattening systems [49]. In
the Maasai community, consumption of unboiled (raw)
milk was associated with increased odds of carriage of E.
coli resistant to single and multiple antibiotics [38]. The
relationship between milk and AMR was linked to con-
sumption of antibiotic-resistant bacteria in contaminated
milk [38]. Nevertheless, the Maasai and other communi-
ties are at a higher risk of diarrhea and other infections,
from other sources. They tend to be greater consumers
of certain types of antibiotics, leading to specific types of
AMR [36]. In general, the spread of drug resistance is
driven by multiple factors, which are linked to human
life activity and travel, animals and the food trade, wild
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Table 1 Risk factors for the emergence and transmission of AMR in East Africa
Antimicrobial resistance
study
Risk factors investigated Significant risk factors Hosts Country Reference
Nasal carriage of methicillin-
resistant Staphylococcus aur-
eus among healthy under-5
children
age, sex, education, visit the
hospital, antibiotic use
– human Tanzania [37]
Multiple ESBL-Producing E.
coli Carrying Quinolone and
Aminoglycoside Resistance
Genes
sex, location, animal type,
breed, antibiotic use
animal type, breed,
antibiotic use
animals Tanzania [12]
Resistant E. coli in three
culturally diverse ethnic
groups
Increased number of water
sources, adherence to
antibiotic withdrawal periods,
shared water resources,
consumption of unboiled
(raw) milk,
increased number of
water sources, shared
water, consumption of
unboiled (raw) milk
Human, animals Tanzania [38]
Antibiotic Resistance in E. coli Higher-income, antibiotics use higher income human Tanzania [39]
Nasal Carriage of Methicillin-
Resistant Staphylococcus
aureus
Duration in health care
services, history of antibiotic
use, history of chronic illness,
duration in health care
services, profession, age,
location of health facilities,
wards,
location of health
facilities, duration in
health care services
human Tanzania [40]
Extended-Spectrum-Beta-
Lactamase-producing
Enterobacteriaceae
Prior admission, prior
medication, currently admitted
in the surgical ward, patient
inside the room, over 4 days of
hospitalization, currently on
the antibiotic, currently on
Ciprofloxacin, currently on
Ceftriaxone, HIV positive,
wound infection
prior admission, currently
on the antibiotic, wound
infection,
human Tanzania [41]
Commonly used
antimicrobial agents in
bacterial pathogens isolated
from urinary tract infections
Age, inpatient, hospitalization
in the last 12 months, UTI in
last 12 months, Urinary
catheter, urinary catheter in
last 12 months, use of other
Antibiotics in the previous 6
months, Ciprofloxacin use in
the previous 6 months, third-
generation Cephalosporin use
in the previous 6 months
Hospitalized (inpatient),
third-generation Cephalo-
sporin use in the previous
6 months, ciprofloxacin
used in the previous 6
months
human Rwanda [42]
Antimicrobial resistance
patterns of phenotype
Extended Spectrum Beta-
Lactamase producing bacter-
ial isolates
Age, sex, department, sample
type, ward/clinic, bacteria
isolate, condition at discharge,
the period of admission (days),
longer hospital stay,
condition at discharge
human Tanzania [43]
Antimicrobial susceptibility
profiles of E. coli and K.
pneumoniae
Age, sex, health centre level,
location of health sub-district,
HSD, history of admission, his-
tory of medical procedures,
surgery, antibiotic use, use of
gentamicin, use of ciprofloxa-
cin, use of septrin
age, level of health facility,
location of health sub-
district, district of
residence, undergoing
medical procedures, use
of septrin
human Uganda [10]
Faecal carriage of ESBL-
Producing
Enterobacteriaceae
Sex, age, place of residence
(district), parent level of
education, children groups,
hospitalized children,
nutritional status, weight-for-
age-Z-score, Length-for-age-Z-
score, eight-for-length-Z-score,
use of antibiotics, HIV
younger age, HIV
infection and use of
antibiotics
human Tanzania [44]
Predictors of blaCTX-M-15 in Age, number of children, sex, age, history of antibiotic human Tanzania [45]
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animals, migration, transportation, as well as water and
wind [54].
Demographic factors
Demographic analysis of AMR is important to reduce
any potential adverse health impact in a timely fashion
to limit the spread of the resistant pathogens. In a hu-
man context, various studies have found an increased
prevalence of beta-lactamase genes with age [37, 44, 45,
55]. In the community settings in Mwanza City,
Tanzania, increasing age was reported as a predictor for
the carriage of ESBL-PE [45]. Similarly, Muvunyi et al.
[42] found an association between increased age with
the prevalence of blaCTX-M Gram-negative bacteria.
Likewise, an increased carriage of blaCTX-M Gram-
negative bacteria in persons over 65-year-old due to re-
peated hospitalization has been reported [55]. Further, it
was hypothesized that due to reduced immunity in
adults over 65, they are more prone to infections caused
by AMR bacterial strains [55]. In Uganda, the carriage of
MDR isolates was significantly associated with age, par-
ticularly the age group between 15 and 44 years [10].
However, contrary to that, Tellevik and colleagues re-
ported age equal to or below 12months to be associated
with ESBL carriage [44]. Furthermore, Tellevik and
others reported that infants compared to older children
were more likely to be colonized with ESBL positive bac-
teria, with the possibly that resistant strains were being
transmitted from mothers to their babies [44].
History of co-morbidities
A history of malnourishment, diseases such as diabetes,
HIV and other infections, were found to be associated
with colonization of AMR bacteria [44, 48]. For instance,
diabetic patients have reduced immunity, predisposing
such patients to MRSA colonization [48]. Similarly, indi-
viduals with HIV are more prone to infections and
hence are more likely to be hospitalized and consume
antimicrobials [44]. Similarly, Cotton et al. [56] reported
the association between HIV and ESBL carriage. The
weak immunity in HIV patients increases the opportun-
ity to acquire various infections [57]. Therefore, HIV
positive pregnant women have been recommended to
use anti-retroviral drugs to reduce mother-to-child
transmission [44]. Despite the association between HIV
and ESBL carriage, the HIV status has not been well
documented as a risk factor for ESBL carriage [44]. Fur-
ther, malnourished children with impaired immunity are
more vulnerable to infections, and therefore more likely
to be treated with antibiotics [44]. Godfrey and col-
leagues reported increased colonization of superficial
skin infection with MRSA due to reduced skin immunity
to fight against MRSA isolates [48].
History of antibiotics use
The previous use of antibiotics has been associated with
the development of AMR [10, 12, 42, 44, 45, 50, 55].
The history of antibiotics use is the main driver in the
development of AMR and hence selection pressure
Table 1 Risk factors for the emergence and transmission of AMR in East Africa (Continued)
Antimicrobial resistance
study
Risk factors investigated Significant risk factors Hosts Country Reference
varieties of E. coli genotypes
from humans
location, antibiotic use,
admission history,
use, history of admission
in the past 1 year
Faecal carriage of CTX-M
extended-spectrum beta-
lactamase-producing
Enterobacteriaceae
Source of income, source of
food, local herbal use, street
children type, primary
education
local herbal use, street
children type
human Tanzania [46]
Antimicrobial Resistance
Profiles and Clonal
Relatedness of Pseudomonas
aeruginosa Strains
age, gender, residence,
antimicrobial source, ease in
accessing over the counter,
prescription availability, dose
completion
self-medication, non-
completion of dosage
human Kenya [47]
Methicillin-resistant
staphylococcus aureus
(MRSA) colonization among
Intensive Care Unit (ICU)
patients and health care
workers
Age, sex, education,
occupation, smoking habit,
history of sickness in past year,
being sick for more 3 times,
being diabetic, illicit drug use,
sex, history of sickness in
past year, being sick for
more 3 times, being
diabetic, illicit drug use
human Tanzania [48]
Inappropriate usage of
selected antimicrobials
Sex, age, breed, place/origin
(rural, urban)
place/origin (rural/urban),
age, breed
animals Uganda [49]
Extended-spectrum-beta
lactamases producing
Enterobacteriaceae
Age in days, sex, admission,
body temperature, oxygen
saturation, skin pustule,
umbilical discharge, history of
antibiotic-baby, maternal fever,
maternal antibiotics, stool ESBL
positive ESBL-PE
colonization of the
mother, history of anti-
biotic use,
human Tanzania [50]
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specific for the type of antibiotic and the bacterial spe-
cies [55, 58–60]. In Tanzania, the history of antibiotic
use and positive ESBL-PE colonization of mothers was
associated with neonatal ESBL colonization in a tertiary
hospital [50]. Moreover, a history of antibiotic use in-
creased the risk of developing antibiotic resistance,
where patients in Tanzania who were on treatment to at
least one antibiotic had an increased risk of blaCTX-M
Gram-negative bacteria compared to those who were
not on any antibiotics [55]. In Rwanda, previous use of
ciprofloxacin and other antibiotics in the previous 6
months was a risk factor contributing to CR [42]. Such
findings also have been reported in other sub-Saharan
African countries, particularly in Cameroon and Guinea-
Bissau, where previous use of antibiotics was associated
with ESBL carriage in hospital settings [61, 62]. How-
ever, this report is contrary to Moremi and colleagues
who reported non-significant relationship between anti-
biotic use and ESBL-producing Enterobacteriaceae car-
riage among street children dwelling in Mwanza city
[46]. Such a relationship was also reported by Fleece
et al. [39], who found non-significant association be-
tween antibiotic use or episodes of diarrhea and anti-
biotic resistance in rural settings in Tanzania. In general,
if the ecological and cultural conditions favour bacteria
transmission, AMR bacteria could emerge irrespective of
antimicrobial use practices in human health [38]. How-
ever, the heterogeneity between studies on the associ-
ation between the previous use of antibiotics and AMR
may be attributed to differences in study designs and the
statistical methods used in data analysis.
Hospitalization
Prolonged stay in hospital and condition at discharge were
significantly associated with ESBL producers [43]. The risk
for AMR is increased especially in patients who had con-
tinued exposure to antibiotics during hospitalization [43].
For instance, Moremi and her colleagues reported that the
ESBL-producing Enterobacteriaceae carriage was signifi-
cantly higher on discharge than admission [63]. In other
studies, being male, a history of sickness in the past year,
and > 3 illnesses within a short time, were associated with
MRSA colonization among patients [48]. Further, the level
of available healthcare and facilities predisposed patients
to AMR [10]. For instance, patients admitted at referral
hospital such as Muhimbili National Hospital had higher
ESBL carriage upon admission than those admitted to a
District Hospital in Dar es Salaam [44]. This finding is also
supported by Seni et al. [64] in which the resistance to
third-generation cephalosporins in E. coli, Klebsiella spp.,
and other Enterobacteriaceae was higher in strains from a
tertiary hospital compared to lower healthcare facilities.
Similarly, at Bugando Medical Centre tertiary hospital in
Mwanza, Tanzania, the MDR was higher in isolates from
children than those from the district and regional hospi-
tals [65]. In Moshi region, Tanzania, patients who came to
the referral hospital at Kilimanjaro Christian Medical
Centre were carrying more resistant bacteria than hospi-
talized patients [55]. This difference increased the risks to
health workers, particularly nurses who had frequent pa-
tient contact, especially when compared to doctors [40].
Nevertheless, the association between MRSA carriage
among healthcare workers and facilities might be attrib-
uted to differences in levels of commitment to control
measures of infection between tertiary and regional hospi-
tals [40]. For example, Moremi et al. [66], reported simi-
larity of genotypes in the intensive care units due to
frequent movement of healthcare workers or instruments,
implying the need to revise cleaning and disinfection pro-
tocols, as well as having the necessary precautions to avoid
hand and clothing contamination during clinical practices.
Genetic diversity, clinical relevance and regional
surveillance of AMR in East Africa
Genetic diversity of AMR genes
Most studies in East Africa have reported considerable
genetic diversity and differences in sequence types of
AMR genes particularly for ESBL (Table 2, Fig. 1), MRSA
(Table 3) [71–75], and CAR (Table 4). These are attrib-
uted to evolutionary events, including mutations, selection
and gene transfer, in the AMR genes in MRSA, ESBL and
carbapenem isolates. In East Africa, ESBL resistance genes
have been isolated from E. coli, Klebsiella spp., Proteus
spp., Enterobacter spp., Pseudomonas aeruginosa, Acine-
tobacter spp., Klebsiella oxytoca, Proteus mirabilis, Entero-
bacter cloacae, Acinetobacter baumanii, Salmonellae spp.
and E. cloacae complex [6–8, 12, 15, 22, 23, 44, 50]. Fur-
ther, proportions and range of antimicrobial resistance
genes obtained from human, animals and environment
differ (Table 5).
The genetic diversity of ESBL genes including blaTEM,
blaOXA-1, blaCMY-2, blaCTX, blaSHV, blaSCO, blaACT,
blaADC, blaCARB, and blaNDM have been collected from
bacterial species sourced from animals, humans and the
environment (Table 2). Such diversity of ESBL produ-
cing bacteria represents a huge challenge for local hos-
pital infection control teams [22]. The ESBL, particularly
blaTEM-, blaSHV-, and blaCTX M-enzyme, exhibit a high
degree of diversity with high levels of MDR [31, 44, 79,
80]. In East Africa, the blaCTX-Ms have been reported
to be the dominant enzymes among the ESBL genes [6–
8, 15, 44, 69, 81]. However, this finding is contrary to re-
ports by Armah [67] in Morogoro region, Tanzania in
which the blaTEM enzymes followed by blaOXA-and
blaCMY-2 were isolated in higher proportion in poultry.
The ESBL are encoded by plasmids and mobile genetic
elements and transferred to other bacteria [82]. The
genetic diversity of plasmid replicons types in humans,
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animals and environmental compartments has been re-
ported in E. coli, K. pneumoniae and E. cloacae ESBL
carrying isolates (Table 2). The IncF plasmids have been
found in E. coli producing ESBL genes collected from ani-
mals, humans and the environment [12, 13, 68, 69]. Fur-
ther, the IncF plasmid types such as IncFIA, IncFIB,
IncFII, IncFIB (K) have been reported in E. coli producing
ESBLs in domestic and companion animals [12], humans
[68], thereby indicating commonality of IncF plasmids
types circulating in humans and animals. Such associa-
tions have also been reported in K. pneumoniae and E. clo-
acae ESBL carrying isolates originating from humans [22,
50, 69] and fish [69]. The IncF types such as IncFIB
(AP001918), IncFIA, IncFII, IncFII (pCoo c) were shared
between animals and humans [13], indicating the possibil-
ity of cross-species transmission of plasmid replicon type
among ESBL-PE genes carrying isolates.
In East Africa, the distribution and the predominance of
the MRSA genes (Table 3) varies between countries. In
Uganda, the SCCmec type 1 and SCCmec type V were the
most common and accounted for between “33.3 - 91.3%”
prevalence [73, 76, 78]. In Kenya, the SCCmec type II
MRSA and a pvl strain of MRSA were significant patho-
gens in patients with soft tissue infections presenting to
hospitals [72]. Further, a cross sectional study in Kenya,
reported predominance of SCCmec type V followed by
SCCmecII genes in healthy students residing within the
university residence halls [83]. Several sequence types
(STs) of MRSA have been reported in East Africa [71, 74,
75, 77]. For instance, the ST88 and ST1797 have been re-
ported to be the predominant sequence types causing
wound infection and abscesses in clinical isolates in a ter-
tiary hospital in Tanzania [74]. In Kenya, ST241 was the
predominant clonal complex in various healthcare institu-
tions in Nairobi [75]. Further, ST239 isolates were associ-
ated with hospital-acquisition in Kenya [77]. The MRSA
carriage isolates have been confined to patients with burns
due to a prolonged stay in the hospital [77]. MRSA iso-
lates were recovered from wound swabs, pus, and nasal
swabs in Lake Victoria, Tanzania, and found the spa types
t690 and t7231, ST88 and ST1797 were dominant among
clinical cases [74]. The two MRSA isolates from wounds
were all typed as ST612 [11]. In Kenya, all the MRSA iso-
lates collected from inpatients in the medical, surgical and
gynecological wards of Thika Hospital were of spa type
t037, linked to internal sources within the hospital [77].
A wide diversity of CAR genes including blaIMP, bla-
VIM-1
bla
SPM-l, blaNDM-1, blaOXA-23 blaOXA-24,
blaOXA-58, blaKPC and novel ADC, blaADC-57 have
been identified in East Africa [28, 33] (Table 4), mostly
isolated from clinical samples in hospital settings. How-
ever, there is no information available on occurrence of
CP bacteria in livestock and their environment in the
East Africa [33]. The genetic determinants of CP have
been reported in P. aeruginosa, A. baumannii, K. pneu-
moniae, Salmonella spp., K. oxytoca, Enterobacter spp.,
Pantoea agglomerans, P. mirabilis, Serratia marcescens,
Pantoea agglomerans, Morganella morganii, Enterobac-
ter sakazaki and Stenotrophomonas spp. (Table 4). The
prevalence of carbapenemase genes isolated from differ-
ent bacterial isolates varies. For instance, Mushi et al. [9]
reported variation in the prevalence of CP genes, in
which the overall frequency of drug resistance loci in E.
coli was 14% (32 isolates) followed by K. pneumoniae
10.57% (24 isolates), P. aeruginosa 10.13%, K. oxytoca
1.76%, A. baumannii 1.3%, Citrobacter freundii 0.88%, S.
marcescens 0.88%, and Salmonella spp. 0.44%). In South
Western Uganda only blaVIM and blaOXA-48 genes
were detected among the carbapenemase-producing En-
terobacteriaceae of clinical origin [30]. However, most
studies have reported low prevalence of the blaNDM-
types. For instance, the blaNDM-1 gene was found to be
uncommon (2.6%) among the bacterial isolates [17], sig-
nifying the low prevalence of the New Delhi Metallo-β-
lactamase 1 (NDM-1) types in the East Africa. The
Table 5 Proportions and range of antimicrobial resistance genes
obtained from various pathogens in humans, animals and
environment
Type of antimicrobial resistance
genes
Range of ESBL genes in
different studies (%)
Mean (n/N;%)
Methicillin resistance S. aureus genes
SSCmec I 0–56.4 21.24
SSCmec II 0–8.3 1.45
SSCmec III 0–100 27.34
SSCmec IV 0–40.5 14.06
SSCmec V 0–91.3 18.70
SSCmec I,II,III 0–50 6.25
SSCmecA 0–100 16.66
Extended spectrum beta-lactamase genes
TEM 0–100 26.7
OXA 0–75 15
CMY 0–62.5 4.81
CTX-M 0–100 45.68
SHV 0–36 7.72
OXA&TEM 0–32 2.46
Carbapenames genes
IMP 0–100 23.75
VIM 0–66.7 18.84
SPM 0–16 0.64
NDMI 0–100 7.59
OXA 0–100 17.91
KPC 0–33.30 5.82
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blaNDM-1 genes have been reported in Kenya [28],
Uganda [17, 31] and Tanzania [9, 31]. The blaNDM-1
genes were for the first time isolated in India and then
reported in Europe and have been identified in exten-
sively drug-resistant A. baumannii [28], raising a con-
cern in the transmission dynamics of these genes in East
Africa. Poirel and colleagues reported identical PGFE
patterns of K. pneumoniae similar to strain 05–506 iden-
tified in Sweden. Strain 05–506 was associated with
intercontinental transmission of the blaNDM-1, by the
Indian population in Kenya, and air traffic between Eur-
ope and East Africa [80]. The blaNDM-1 gene has been
found co-existing with other CP genes, thereby explain-
ing why these isolates are MDR [17]. In Kenya, the
blaNDM-1 carbapenem-resistant NDM-1-positive K.
pneumoniae isolates were clonally related and expressed
other ß-lactamases genes including the blaCTX-M-15,
blaOXA-1, blaOXA-9, blaCMY-6 and aminoglycoside re-
sistance methylase RmtC genes [80]. Further, all isolates
that carried the blaNDM-1 carbapenemase gene were
clonally related and expressed many other resistance de-
terminants, including β-lactamases blaCTX-M-15,
blaOXA-1, blaOXA-9, blaCMY-6, and aminoglycoside re-
sistance methylase RmtC [80]. In Tanzania, Mushi and
colleagues found solitary and heterogenous MDR gram-
negative bacteria having at least two carbapenemase
genes [9].
Trends in the carriage of antimicrobial resistance genes
of the recovered isolates overtime period
Figure 2 represents the ESBL, MRSA, and CAR carriage
rates over time, as established by a linear regression
model using the values reported in screened studies con-
ducted from 2001 to 2018 in East Africa. Over this
period, the differences in ESBLs, MRSA, and carba-
penem carriage rate in screened studies in East Africa
were insignificant (p-value = > 0.05). The data obtained
with period on carriage rate between ESBL and CAR [p
value = 0.1; 95% CI = − 0.5 to 1.9%], ESBL and MRSA (p
value = 0.9; 95% CI = 1.9 to 1.8%] and CAR and MRSA;
[p value = 0.6; 95% CI = − 1.9 to 2.5%] were insignificant.
However, AMR gene carriage in recovered isolates is on
the rise and increased from 2001 to 2016, 2005 to 2016,
and 2001 to 2012 for CAR, MRSA, and ESBLs respect-
ively. The highest AMR genes carriage rates for CAR
(18.2%), ESBL (13.1%), and MRSA (24.25%) were re-
ported in studies conducted from 2013 to 2016, 2009–
2012, and 2013–2016 respectively. The rise of ESBL,
CAR, and MRSA carriage rates in East Africa pose a
threat to public health particularly in the geographical
areas where the rates are very high. A limitation of this
analysis is the fact that these data were collected from
unlinked cross-sectional studies conducted in different
geographical areas in East Africa; consequently, some
important information may have been missed.
Fig. 1 Geographical distribution of the sequence types from pathogens originated from various sources in the East Africa
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Clinical relevance and outcome of the AMR genes in East
Africa
The genetic diversity at antibiotic resistance loci could
determine a population’s capacity to cope with future
challenges of the antimicrobial drugs used for infection
control [84]. The genetic diversities of AMR genes par-
ticularly ESBLs, MRSA, and CAR among clinical isolates in
East Africa pose a public health threat. In East Africa, the
ESBL, particularly TEM-, SHV-, CTX M-enzyme, exhibit a
high degree of diversity [79, 80], associated with high levels
of MDR [44]. The ESBLs are encoded by plasmids which
also carries genes encoding for other drugs, limiting the
antibiotic options in the treatment of ESBL producing or-
ganisms [85]. Carbapenems have been considered as the
drug of choice for infection associated with ESBL-
producing organisms. However, challenges remain as resist-
ance to carbapenems has recently been reported, and there
have been treatment failures [85]. The ESBL-producing
organisms may appear susceptible to some extended-
spectrum cephalosporins [85]. However, alternative treat-
ment options to cephalosporins are limited in local settings.
In Uganda, a high prevalence of carbapenem and CAR
encoding genes among third-generation cephalosporins re-
sistant Enterobacteriaceae have been reported in clinical
isolates obtained from patients referred to Mulago hospital.
Furthermore, high resistance rates in third-generation
cephalosporin cefotaxime among urinary tract infection iso-
lates have been recovered from pregnant women at
Muhimbili National Hospital in Tanzania [86].
The high MRSA carriage rates among patients and
health workers in the East Africa is a concern given poor
infection prevention and control measures in our set-
tings [87]. In Kenya, the trend in antibiotic susceptibility
to MRSA declined between years 2014 to 2016, just like
the methicillin susceptible counterparts [87]. In Kenya,
MRSA is susceptible to linezolid, tigecycline, teicoplanin
and vancomycin [87], quinupristin/dalfopristin, nitrofuran-
toin, and ampicillin/sulbactam [88]. Further, high resistance
to commonly used antibiotics such as gentamycin, erythro-
mycin, levofloxacin and tetracycline has also been reported
in Kenya [88]. In Tanzania, high resistance rates among
MRSA isolates to kanamycin, gentamicin, ciprofloxacin and
trimethoprim-sulphamethoxazole have been reported [40].
Low resistance rates against MRSA isolates have been re-
ported to mupiroaazcin and none toward linezolid, indicat-
ing that these two drugs can be used as a treatment options
for MRSA infections in our settings [40]. In Uganda, the
coexistence of hospital and community-associated MRSA
have been fueled by pre-exposure to ampicillin and co-
trimoxazole/or health care facilities in children [16]. Such
coexistence presents a challenge for management of MRSA
infection in outpatients.
Strategies and future for regional surveillance of AMR in
the East Africa
The World Health Organization, the Food and Agricul-
ture Organization of the United Nations and the World
Organization for Animal Health has advocated for a hol-
istic and multisectoral approach to address the AMR
problem. This has been strengthened by the collabor-
ation of regional consortia involving local and regional
academic and research institutions in Africa, and a joint
dedication of efforts to fight against infectious diseases
in animals, humans and their environments. Regional
consortia such as the SACIDS Foundation for One
Health in collaboration with the London School of
Hygiene and Tropical Medicine, London International
Development Centre, Royal Veterinary College, Chatham
Fig. 2 Trends in Extended Spectrum beta-lactamase, Methicillin resistance Staphylococcus aureus and carbapenem genes in recovered isolates in
East Africa
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House of the Royal Institute of International Affairs in the
United Kingdom and the American Society of Microbiol-
ogy of the United States, have partnered to address AMR
problem through research and training. Strategically, sur-
veillance is being supported by phenotypic and genomic
data, to understand the flow of resistomes across human,
animal and environmental compartments. For instance,
research programs focused on genomic epidemiology of
ESBLs producing E. coli in humans, animals and their
environments are conducted by postgraduate students of
the SACIDS Foundation for One Health at the Sokoine
University of Agriculture and Muhimbili University of
Health and Allied Sciences in Tanzania. This work is
attempting to understand the transmission dynamics of
AMR genes and their virulence [89], and will provide a
model for the surveillance of AMR in Africa, including an
exemplar of implementing global recommendations and
local solutions. More generally, surveillance will be per-
formed in line with the national AMR action plans to es-
tablish a nation-wide surveillance system for AMR,
establish and build capacity for a national reference la-
boratory and designated laboratories for AMR surveillance
using an integrated One Health approach. SACIDS Foun-
dation for OH in collaboration with the American Society
for Microbiology through the Fleming Fund initiative will
implement the Tanzania National Action Plan for AMR
launched in 2017. Further, through funding from the
Medical Research Council in the United Kingdom, policy
gaps, behaviour, socio-cultural and economic determi-
nants for AMR in communities will be identified to pro-
vide evidence-based policy by policy makers to solve the
AMR problem in Tanzania.
The implementation of effective and sustainable AMR
surveillance programmes in Africa is hampered by a lack
of infrastructure and other resources required to per-
form optimal surveillance [90]. Most laboratory facilities
in resource-limited countries produce quality routine
culture and susceptibility testing, which is both cost-
effective and provides high-quality surveillance data.
However, developing countries should consider incorp-
oration of the whole genome sequencing in the diagnosis
framework of drug resistance isolates. The MDR isolates
present a challenge for management of clinical cases in
resource-limited countries. Resistance to colistin, which
is a last resort treatment for life-threatening infections
caused by Enterobacteriaceae, including MDR pathogens
has been reported in several countries and regions.
Other infections such as MDR tuberculosis (MDR-TB)
pose a threat to public health in the Sub Saharan African
countries adding to the current long-standing pandemics
of HIV in the region. Studies have found high diversity
of mutations among MDR-TB patients, suggesting estab-
lished and ongoing transmission of MDR-TB strains or
multiple sources of infections [91]. However, it is
unclear whether the role played by drug resistance gen-
etic mutations in combination or alone could predict the
disease manifestations or progression. Therefore, clinical
studies have been proposed to evaluate the incorpor-
ation of whole genome sequencing in the diagnostic
framework of drug resistance tuberculosis in these coun-
tries. It has been thought that the incorporation of whole
genome sequencing as a diagnosis tool for MDR-TB in
resource limited settings will improve the diagnosis and
treatment of TB while providing stringent strain dis-
crimination. Such incorporation would improve the de-
tection of drug resistance mutations in TB patients, and
to inform clinical and treatment decision making [92].
The information obtained from such clinical studies
could support policy change in the adoption of molecu-
lar TB diagnostic algorithms in resource-limited
countries.
Conclusions
The high genotypic diversity of the AMR genes among
the bacterial isolates might suggest possible exchange of
strains or a flow of genes among different strains due to
transfer by mobile genetic elements or multiple sources
of resistance bacteria. Such levels of diversity prompt the
calling for immediate interventions, including guidelines
concerning antibiotics use and regulations governing
their importation and sale. However, antibiotic use and
regulation is likely to be a very complex system because
other factors such as cultural and ecological conditions
favour transmission of bacteria. There is a high likeli-
hood that people will have AMR bacteria irrespective of
how antibiotics are used. Therefore, control strategies
against AMR need to be tailored, beyond antibiotic use
and availability, to local practices that affect bacterial
transmission. Moreover, the trend of ESBL, MRSA and
CAR carriage rates is dynamic and are on rise over time
period, posing a public health concern in East Africa. In
addition to that, phenotypic and genotypic drivers of
AMR should be investigated within an integrated One
Health framework. Such investigations will inform trans-
mission dynamics of resistomes across compartments,
and facilitate information sharing for informed decision
making; ultimately, reducing the spread of AMR genes
in bacteria. Further, the application of advanced tech-
niques such as whole genome sequencing for detection
of AMR could cut a bridge between clinical research and
care, so that case management and treatment decisions
can be informed and personalised.
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